In a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after the ...
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing ...
Live audio/video webcasts of these presentations will be accessible through Eikon’s investor relations website at ...
This release fulfills the Company's October 20 announcement that next-round results on the expanded human-submitted dataset ...
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development ...
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and ...
Nuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in ...
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company ...
Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in ...
Presentation to be given at the 2026 Society for Neuro-Oncology Annual Meetingwill highlight two high grade glioma patients ...
Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary ...
About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results